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Abstract
Background: DNA methylation at CpG dinucleotides is modified in tumorigenesis with potential impact on
transcriptional activity.
Methods: We used the Illumina 450 K platform to evaluate DNA methylation patterns of 50 metastatic melanoma
tumors, with matched gene expression data.
Results: We identified three different methylation groups and validated the groups in independent data from The
Cancer Genome Atlas. One group displayed hypermethylation of a developmental promoter set, genome-wide
demethylation, increased proliferation and activity of the SWI/SNF complex. A second group had a methylation
pattern resembling stromal and leukocyte cells, over-expressed an immune signature and had improved survival
rates in metastatic tumors (p < 0.05). A third group had intermediate methylation levels and expressed both
proliferative and immune signatures. The methylation groups corresponded to some degree with previously
identified gene expression phenotypes.
Conclusions: Melanoma consists of divergent methylation groups that are distinguished by promoter methylation,
proliferation and content of immunological cells.
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Background
The tumor phenotype is formed by genetic and epigen-
etic events and signals from the micro-environment. In
melanoma, the landscape of somatic mutations and gene
copy number changes has been explored [1–3], and the
understanding of surrounding immunological cells has
led to the development of new treatment options [4, 5].
Recurrently mutated genes discovered by recent exome
sequencing studies are frequently involved in epigenetic
modifications [6], e.g., ARID2 [1, 2], pointing to a yet
under-appreciated driver role of epigenetic factors.
Methylation of cytosine in the CpG context is an epigen-
etic mark that can directly influence transcriptional ac-
tivity, and changes of DNA methylation pattern have
been associated with tumorigenesis. In melanoma, a
number of genes were found to harbor promoter CpG
island methylation [7]. Consequently, melanomas hyper-
methylated at several CpG islands were termed CpG
Island Methylator Phenotype (CIMP) [8], according to
findings from other cancer types [9, 10]. Promoter
methylation is reported to repress gene expression.
Conversely, a small number of genes, such as MAGE,
are activated by hypomethylation in melanoma [7].
High-throughput technology has enabled the assessment
of DNA methylation of a wider spectrum of genomic
locations in melanoma [11–23], often highlighting
methylation events that discriminate melanoma from
nevi/melanocytes. Genome-wide methylation patterns
may reveal tumor subtypes of biological and clinical
relevance. In this respect, Thomas et al. used the
Illumina GoldenGate platform (1505 CpGs) and found
three methylation subgroups in 47 primary cutaneous
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melanoma, with the hypermethylated groups having in-
creased Breslow thickness [24]. Sigalotti et al. analyzed
short-term cultures from 45 stage IIIC patients on Illu-
mina 27 K BeadChips and identified one group with low
and one with high average methylation, respectively;
with the latter group having poor overall survival [25].
Previously, we introduced four gene expression sub-
groups in melanoma; one proliferative group (‘Prolifera-
tive’), one group with activated melanogenesis pathway
(‘Pigmentation’), one group displaying elevated immune
response (‘High-Immune’) and one with contribution
from surrounding normal tissue (‘Normal-like’) [26].
The groups were also present in primary melanomas
and had diverging clinical outcome [27]. In this study we
aimed to characterize DNA methylation subtypes of
melanoma, validate the findings in independent data,
and to investigate the relationship of methylation and
gene expression patterns.
Results
Identification of three methylation subtypes in melanoma
We determined the methylation status of more than
480,000 individual CpGs in 50 metastatic melanoma tu-
mors, subsequently called ‘Bergen’ data, that were in-
cluded in a previous discovery of gene expression
phenotypes [26] (Table 1). The methylation measure-
ments are β-values that range from 0, unmethylated to
1, fully methylated [28]. We defined a set of CpGs that
is aberrantly methylated in melanoma as compared to
melanocytes, with 9,886 melanoma-methylated CpGs
and 5,236 melanoma-demethylated CpGs, respectively,
as previously described [29]. Unsupervised clustering of
the combined CpG sets identified three consensus
groups in the Bergen melanomas, subsequently called
methylation subtype 1, 2 and 3 (MS1, MS2, MS3)
(Fig. 1a). As validation data, we used 242 samples from
The Cancer Genome Atlas (TCGA) (Table 1). Unsuper-
vised clustering of the TCGA data, which consists of pri-
mary and metastatic tumors, using the same CpG set,
resulted in three groups with comparable methylation pat-
terns to the Bergen data (Fig. 1a). Principal component
analyses were performed to exclude that the groups are
due to technical procedures at data generation, such as
the use of different batches (Additional file 1: Figure S1A
and B). The three groups were re-identified in both data-
sets when changing the number of CpGs to be included in
the clustering procedure (Additional file 1: Figure S1C).
We next classified the TCGA samples into MS1, MS2,
and MS3 groups using Bergen-derived methylation cen-
troids (Additional file 2: Table S1). Centroid classification
was the dominant explainer of total variation in TCGA
methylation data compared to histopathological and
molecular factors (Additional file 1: Figure S1B). Further-
more, classification of TCGA tumors using Bergen-
derived centroids, is in good agreement with the groups
obtained from unsupervised clustering of the TCGA data
(76 % sample co-occurence, P < 2x10−16, Additional file 1:
Figure S1D and “MS classified” annotation in Fig. 1a),
confirming that the methylation clusters of Bergen are re-
identified in the TCGA data.
We then restricted the analysis to a subset of CpGs lo-
cated in CpG islands within 1500 bp upstream of tran-
scription start sites. The vast majority of these promoter
island CpGs were hyper-methylated in melanomas (930
of 947), in line with other tumor types. In both datasets,
methylation levels spanned a continuous gradient from
unmethylated melanomas to fully methylated melanomas,
Table 1 Patient and sample information
Feature Bergen (n = 50) TCGA (n = 242)
Gender
Male 28 (56) 154 (64)
Female 22 (44) 88 (36)
Median thickness (mm) 2.25 (0.5-25) 2.7 (0.28-50)
Clark
I 3 (9) 3 (2)
II 2 (6) 13 (7)
III 9 (27) 49 (27)
IV 13 (39) 83 (46)
V 6 (18) 31 (17)
Histogroup
SSM 18 (53) -
NM 16 (47) -
Sample origin
Primary 0 27 (11)
Regional LN 3 (6) 134 (56)
Regional other 0 49 (20)
Distant metastasis 47 (94) 31 (13)
BRAF mutation
yes 25 (50) 118 (49)
no 25 (50) 123 (51)
NRAS mutation
yes 11 (22) 66 (27)
no 39 (78) 175 (73)
CDKN2A-arrayCGH
Homozygous Deletion 11 (22) -
Present 39 (78) -
Gene expression phenotype
High-immune 15 (30) 69 (32)
Normal-like 3 (6) 33 (15)
Pigmentation 20 (40) 63 (29)
Proliferative 12 (24) 49 (23)
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rather than forming a distinctive CIMP group (Additional
file 1: Figure S2). We conclude that in melanomas the full
range of CpGs provides additional information to the
traditionally studied promoter island CpGs, and allowed
for the identification of three reproducible methylation
subtypes, MS1/2/3.
Biological processes shaping the methylation subtypes
Methylation levels at promoter islands are elevated in
MS1 tumors in comparison to MS3 tumors (Fig. 1b,
Kruskal-Wallis test). ‘Poised promoters’ are character-
ized by Polycomb-complex 2 (PRC2) induced H3K27
tri-methylation marks in addition to H3K4 tri-
methylation marks, and are most prevalent in embryonic
stem cells [30]. The poised promoter set of embryonic
stem cells is important in developmental processes and
found to be methylated in various cancer types [31, 32].
Notably, CpGs in this poised promoter set also displayed
increased methylation levels in the MS1 group. Con-
versely, intergenic methylation levels away from genes
and islands are reduced in MS1 tumors (Fig. 1b,
Kruskal-Wallis test). The MS1 group showed a pattern
similar to melanocytes but with hyper-methylation at
many poised promoters. The nine melanoma cell lines
also displayed the MS1 pattern (Fig. 1a). In contrast, the
DNA methylation pattern of the MS3 group was similar
to peripheral blood leukocytes. Finally, the MS2 group
presents a mixture of MS1 and MS3 methylation
patterns with intermediate methylation levels for the
majority of CpGs.
The CpG set used for group discovery consisted of
four functional clusters (Fig. 1a). First, one CpG cluster
(Fig. 1a, black cluster “Cl. 1 + 2”) was highly enriched in
the aforementioned Polycomb-targeted poised pro-
moters. This CpG cluster was hypermethylated in mel-
anoma compared to melanocytes with gradually
increasing methylation levels from MS3 to MS1 tumors.
Second, genome-wide hypomethylation was observed in
repetitive, heterochromatic regions, that had gradually
decreasing methylation levels from MS3 to MS1 tumors
(Fig. 1a, grey cluster “Cl. 5”). Third, a heterogeneous
CpG cluster was found that had opposite methylation
status in melanocytes and blood leukocytes, with melan-
oma samples spanning the gradient in between (Fig. 1a,
green cluster “Cl. 3 + 4”). The fourth cluster of CpGs
could not be assigned to a biological function (Fig. 1a,
‘mixed’, pale blue cluster “Cl. 6”). As the third cluster
seemed to contain methylation signals from non-tumoral
cells, we used the ESTIMATE algorithm to further investi-
gate the cellular composition of the tumors [33]. Evidence
of elevated stromal and immune cell content was ob-
served in MS2/3 compared to MS1 samples (Fig. 2a,
Kruskal-Wallis test). Overall, tumor purity was estimated
to be lowest in MS3 samples and highest in MS1 samples
(Fig. 2a, Kruskal-Wallis test). Furthermore, MS1 and MS2
over-expressed mitotic gene signatures, whereas MS2 and
MS3 over-expressed an immune response signature
(Fig. 2b, ANOVA). These observations were validated in
TCGA data (Additional file 1: Figure S3). In conclusion,
the molecular subtypes are shaped by various degrees of
promoter hypermethylation, genome-wide hypomethyla-
tion, and cell-type specific methylation signatures from
the micro-environment.
Methylation processes of melanoma in comparison to
other cancer types
To set the methylation processes of melanoma in con-
text to other cancer types, we used TCGA data from
colon cancer (295 tumors, 38 normal tissues), breast
cancer (201 tumors, 40 normal tissues) and lung cancer
(lung adenocarcinoma, 452 tumors, 32 normal tissues).
For these cancer types, we derived tumor-methylated
and tumor-demethylated CpGs in the same way as for
our melanoma data. The majority of methylated and
demethylated CpGs occurred in only one cancer-type
(Additional file 1: Figure S4A). Yet, at the gene level the
agreement across cancer types was larger, particularly
the agreement of methylated genes was considerable
(Additional file 1: Figure S4A). Importantly, for all inves-
tigated cancer types, the methylated CpGs were located
within poised promoters (i.e. PRC2 target genes), and
the demethylated CpGs located within heterochromatic
regions of ES cells chromatin (Additional file 1: Figure
S4B). Similarly, for melanocyte chromatin states, methyl-
ated CpGs were situated in bivalently marked chromatin
regions, and demethylated CpGs in quiescent/repressed
regions (Additional file 1: Figure S4C). In an aim to
find melanoma-specific mechanisms of methylation, we
(See figure on previous page.)
Fig. 1 Three melanoma methylation subtypes. a Methylation lanes from left to right: 3 methylation subtypes (MS) from Bergen tumors, 9 cell
lines, blood leucocytes, melanocytes (two lanes of each light, medium and dark melanocytes), dermal epidermis, dermal fibroblasts; and 3
unsupervised groups from TCGA tumors. Beta values in heatmap are from unmethylated, blue to methylated, yellow. Cluster lane displays the four
main CpG probe clusters of the 9,886 melanoma-methylated and 5,236 melanoma-demethylated CpGs, using unsupervised hierarchical clustering
in the Bergen data. Island lane: black = CpG island, dark grey = shore/shelf, light grey = open sea. Chromatin lane refers to embryonic stem cell
chromatin states. GEX = gene expression. CDKN2Adel = homozygous deletion of the CDKN2A locus. b Mean beta value across MS subtypes in
different genome-wide CpG sets. Promoter & Island = annotated as TSS200 or TSS1500 (i.e. up to 1500 bp from transcription start site) and
annotated as CpG Island, n = 57,579 CpGs. Away from genes and Island = no annotation for gene and island, n = 42,728 CpGs. Poised
promoter = embryonic stem cell chromatin state, see panel A, n = 59,901 CpGs. P-value from Kruskal-Wallis test
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compared genes hypermethylated exclusively in melan-
oma to genes hypermethylated in colon, lung and
breast cancer. Genes exclusively methylated in melan-
oma were significantly enriched for the GO-terms
“catalytic activity”, “nucleoside-triphosphatase regulator
activity” and “GTPase regulator activity” (false discovery
rate (fdr) < 5 %). This may allow speculating that a meta-
bolic process exists in melanocytes that is connected to
the MAPK pathway via regulation of GTPase (e.g., Ras)
activity, with methylation of the regulators emerging at
tumorigenesis. In summary, aberrant methylation in tu-
mors preferentially occurs at genes with “poised pro-
moters” and demethylation in heterochromatin, however,
the exact stretches of DNA that get aberrantly methylated
are cancer-type specific. This resembles findings from
Sproul et al., who however had not included melanomas
in their study [34].
Correlation to histopathology, mutation data and clinical
outcome
Overall the proportions of the three methylation groups
were comparable between the Bergen and TCGA sam-
ples. However, the TCGA distant metastasis samples
contained more MS1 samples than the Bergen cohort
(Fig. 3a, Fisher’s exact test). We did not observe any sig-
nificant associations of gender, age, primary tumor fea-
tures (Breslow thickness, Clark’s level, SSM/NM), LDH,
lymph-node/subcutaneous, CD3 or CD20 IHC with the
methylation groups in the Bergen data. Furthermore, in
our data, neither BRAF nor NRAS mutation status was
clearly associated with either subgroup (Fig. 1a). Homo-
zygous deletions of the CDKN2A locus seemed to be
more frequent in MS1 (p = 0.02). We repeated the muta-
tion analysis for TCGA exome-sequencing data. The
total number of mutations in tumors was equally distrib-
uted across subtypes (Additional file 1: Figure S5A). For
mutations in 15 known melanoma driver genes [1, 2] we
did not observe any subtype association, with an fdr <
10 % (Additional file 1: Figure S5B). IDH1 hotspot muta-
tions at R132 correlate with a glioblastoma hypermethyla-
tion phenotype [35] and have been reported in melanoma
[36]. IDH1 hotspot mutation was more prevalent in the
hypermethylated MS1 group (6 of 11 mutated cases),
however, not reaching significance.
Disease-specific survival analysis indicated more ag-
gressive behavior of MS1 melanomas compared to MS2/
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3 melanomas, although not reaching significance (p = 0.2
log-rank test, Fig. 3b). This trend was further supported
in metastatic TCGA tumors, with MS1 patients having
inferior survival outcome (p = 5x10−5, Fig. 3c). As sam-
ples from distant metastases are over-represented in the
MS1 subtype, we repeated the survival analysis using
only the regional lymph node metastasis from TCGA,
and again observed inferior survival of MS1 patients
(p = 0.008, Fig. 3d). The primary TCGA cohort size
(n = 27) was too small to allow for survival analysis.
A link between methylation and gene expression
phenotypes
The MAPK and PI(3)K pathways are instrumental in
melanoma [37, 38]. However, these pathways did not
seem to be differentially expressed across methylation
subtypes in Bergen and TCGA data, with the exception
of DUSP genes (Additional file 1: Figure S6A). Genes
that promote the cell cycle, such as MDM2, CDK4,
CDK6, CCND1, CCNE1 and E2F3 are up-regulated in
MS1 samples; as well as genes that directly modify CpG
methylation, such as de-novo methyltransferase DNMT3A
and 5-hydroxy converting TET1 (fdr < 5 %, Fig. 4a,
ANOVA with Benjamini-Hochberg fdr). Histone modi-
fiers were generally not differentially expressed across
methylation subtypes, again with an exception, the H3K4
de-methylation enzyme JARID1B. Recently, members of
the SWI/SNF chromatin remodeling complex have been
found to carry loss-of-function mutations across cancer
types, implying a tumor suppressor role [39, 40]. Interest-
ingly, several SWI/SNF members are up-regulated in MS1
tumors (Fig. 4a).
To further investigate the relationship of methylation
to gene expression patterns, we compared the methyla-
tion subtypes to the four gene expression phenotypes
previously defined in the Bergen cohort [26]. MS1 con-
sisted of ‘Proliferative’ and ‘Pigmentation’–type tumors
(Fig. 4b), suggesting a link between proliferation and
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hyper-methylation. The MS3 subgroup is dominated by
‘High-immune’ and ‘Normal-like’ tumors. The agreement
of gene expression subtypes and methylation subtypes is
statistically significant (p = 0.0001, Fisher’s exact test,
Cross-table Additional file 1: Figure S6B), with methyla-
tion subtypes providing additional stratification beyond
Bergen, p = 0.0001 
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gene expression subtypes. The co-occurrence of methyla-
tion and gene expression phenotypes was also observed in
the TCGA data (p = 6x10−14, Fisher’s exact test, Fig. 4b
and Additional file 1: Figure S6B). Together, these findings
provide a link between the transcriptional and DNA
methylation landscapes in melanoma.
Discussion
In the present study, we have identified three groups of
melanoma specimens with different methylation pat-
terns. The MS1 group fits the paradigm of genome-wide
de-methylation and focal promoter hyper-methylation in
tumors [41]. Most cancer types studied by the TCGA
consortium, contained a subgroup with high methylation
levels [42]. Hypermethylated subgroups in colon and
endometrial cancer were associated with MLH1 inactiva-
tion and increased mutation rate. In other cancer types
hypermethylated subgroups were associated with IDH1
mutations (AML, glioblastoma), or EBV virus (gastric
cancer). For breast cancer, lung squamous cell carcin-
oma and lung adenocarcinoma, there has been no clear
association of the methylated group to such a factor.
Likewise, our melanoma hypermethylated group MS1
was not significantly associated with a mutated gene or
overall mutation rate. Hyper-methylation is primarily di-
rected towards the embryonic PRC2 target gene set.
These genes are pre-marked by histone H3K27 tri-
methylation in addition to a H3K4 mark in embryonic
stem cells [43]. DNA methylation of these ‘poised pro-
moters’ has emerged as a general process across tumor
types [31, 44]. Genome-wide de-methylation in melan-
oma occurs in repetitive regions, distant from CpG
islands. A relatively small number of de-methylated
CpGs are captured on the array, which is likely due to
difficulties with designing probes in repetitive region-
s.Cell line methylation patterns differed from normal
melanocytes and matched well with the MS1 group.
Moreover, methylation subtypes seemed to be influenced
by the cellular composition of the tumor, in particular,
the MS3 methylation pattern is closely related to blood
leukocytes and has a reduced tumor cell content com-
pared to MS1. In the future, single-cell sequencing may
clarify the methylation pattern of pure MS3 tumor cells.
However, for prediction of immune therapy success, in-
formation from both tumor and surrounding cells has
been valuable [45–48]. Therefore, methylation signals
from the micro-environment may prove useful for deci-
sion making in melanoma.
Together, the methylation data reveals two tumor
strategies (Fig. 4c). First, a proliferative strategy that co-
occurs with hypermethylation of poised promoters.
Poised promoters are located in differentiation genes,
some of them potentially negative for tumor fitness. It is
therefore tempting to speculate that methylation of
poised promoters is aimed at removing the brakes of
tumor proliferation. Sequential methylation of the poised
promoter set may inactivate repressive developmental
genes, resulting in a small advantage in tumor growth.
Therefore, clones with ever-increasing poised promoter
methylation may be preferred in tumor evolution. Ac-
cordingly, instead of a clear CIMP group, we observe a
gradual increase in promoter methylation. This prolifer-
ation strategy also seems to act independently from the
MAPK and PI(3)K signaling pathways (Additional file 1:
Figure S6A). The second strategy is based on an inter-
play of tumor cells with immune cells. The composition
of the immune cells in the melanoma samples was pre-
served across cohorts, as the methylation subtypes could
be validated in the independent TCGA data. The precise
interplay of tumor and immune cells is still unclear. The
knowledge of this interplay may reveal the basis of im-
proved survival of MS3 patients, and could greatly bene-
fit the development of further immune therapies.
Importantly, immunomodulating agents have demon-
strated significant clinical benefit in melanoma and
include immune checkpoint blockade agents such as
anti-CTLA4 and anti-PD1/PDL1 [4, 5]. In contrast,
tumor-associated macrophages, regulatory T-cells and
myeloid-derived suppressor cells can blunt anti-tumor
effector functions and promote tumor growth and inva-
siveness, highlighting the complexity of the interplay be-
tween the tumor and the immune system.
A major limitation of the current study is that DNA
methylation is the only investigated epigenetic mark.
Characterization of a broad spectrum of epigenetic
marks will most likely enhance insight into melanoma.
In addition, a better understanding of the functional role
of the SWI/SNF chromatin remodeling complex and its
impact on the epigenetic landscape will be very useful.
Conclusions
Herein, we identified three methylation subgroups in
melanoma, with distinct biological properties and dis-
ease outcome. The methylation groups are in good
agreement with gene expression phenotypes, and high-
light two different mechanisms underlying this disease, a
proliferative strategy and a strategy based on the
presence of immune cells.
Methods
Generation of genome-wide methylation data
We determined genome-wide methylation levels in 50
tumors from Haukeland University Hospital in Bergen
[26], 9 melanoma cell lines (A2058, A7, CHL1, HT144,
MM383, SKMEL3, SKMEL5, WM239A, WM852), light,
medium, dark melanocytes, dermal epidermis and fibro-
blasts (Science Cell Research, USA), and peripheral
blood leukocytes (Promega), using Illumina Infinium
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HumanMethylation450K BeadChips. Informed consent
was obtained from all patients. The study was approved
by the local ethics committee. DNA was extracted as
described previously [26]. Bisulfite conversion and
hybridization to Infinium HumanMethylation450K
BeadChips was performed following the manufac-
turer’s instructions, with samples being processed as
one batch. Methylation data had been deposited at
Gene Expression Omnibus as series GSE51547, and
gene expression data as GSE22153.
Processing of Bergen methylation and gene expression
data
Beta-values were calculated from methylated (M) and
unmethylated (U) signal, as beta =M/(M +U). A total of
496 missing values were imputed using k-nearest neighbor
imputation (k = 10) [49]. For each sample we performed a
peak-based correction of Illumina I and II chemical assays
similar to Dedeurwaerder et al. [50]. For each assay the
beta values were smoothened (Epanechnikov kernel)
to estimate unmethylated and methylated peaks, re-
spectively. The unmethylated peak was moved to 0
and the methylated peak to 1 using linear scaling,
with beta-values in between stretched accordingly and
capped at 0 and 1. CpGs of chromosomes X and Y
were removed.
The matched gene expression data was processed as
described previously [26]. Multiple probes for a gene
(based on gene symbol) were median-merged.
Processing of TCGA methylation and gene expression
data
Methylation data for 242 samples from the TCGA data
portal https://tcga-data.nci.nih.gov/tcga/ were processed
as described for the Bergen data. For a subset of 214
samples we downloaded normalized RSEM gene counts
from ‘level 3’ RNA sequencing data. The data was
quantile-normalized using limma [51], added an offset
of 32, capped to a maximum value of 65,000, log2 trans-
formed, and genes were median-centered. The samples
were classified using reported gene expression pheno-
type centroids as described [26]. TCGA methylation data
for colon cancer (COAD, 295 tumors, 38 solid normal
tissues), breast cancer (BRCA, 201 tumors, 40 solid
normal tissues, constituting the first six TCGA batches)
and lung adenocarcinoma (LUAD, 452 tumors, 32 solid
normal tissues) were processed as described for the
Bergen data.
Clustering procedure to obtain consensus clusters
The set of 9,886 melanoma-methylated CpGs was defined
as β < 0.1 in melanocytes and β > 0.5 in at least 20 % of tu-
mors (n = 10). The set of 5,236 melanoma-demethylated
CpGs was defined as β > 0.9 in melanocytes and β < 0.5 in
at least 20 % of tumors (n = 10), respectively. The CpG
sets were combined for the clustering procedure. Hier-
archical Clustering Analysis (HCA) with Euclidean
distance and Ward’s algorithm for agglomeration, was
performed for 1000 bootstrapped versions of the data
[44]. At each bootstrap HCA the dendrogram is cut
into either 2 or 3 clusters. For all sample pairs, the fre-
quency with which the two samples have clustered
into the same group is calculated. The co-clustering
frequency matrix is then reordered by HCA (Pearson
correlation distance, Ward agglomeration) to obtain the
consensus methylation groups, i.e. subsets of samples that
repeatedly cluster together.
Nearest Centroid Classification
The centroids of the methylation subgroups were defined
as the mean methylation values of the 9,886 melanoma-
methylated and 5,236 melanoma-demethylated CpGs,
across each subgroup of the Bergen samples. Therefore, we
obtained three centroids, one for MS1, one for MS2, and
one for MS3, presenting the mean beta-values of the sub-
groups. The centroids were deposited as Additional file 2:
Table S1. To classify a sample from the TCGA Human-
Methylation450K data, the beta-values of the centroid
CpGs were extracted. The Euclidean distance of the TCGA
beta-values to each of the three centroids was calculated
and the sample was assigned to the MS subgroup to whose
centroid it had the shortest distance. Using this classifica-
tion system we assigned each TCGA tumor as being either
MS1, MS2 or MS3.
Statistical analysis
We used chromatin predictions for H1 embryonic stem
cells [52], and melanoma gene co-expression modules
for ‘Immune Response’ and ‘Cell Cycle’ from an inde-
pendent cohort [53]. All statistical analysis was per-
formed in R 3.1.1. Survival analysis was performed using
the survival package, principal component analysis was
performed using the swamp package [54], ESTIMATE
scores were derived using the estimate package [33].
Additional files
Additional file 1: Figure S1. Robustness of methylation subtypes.
Principal component analysis to monitor data bias due to technical
variables in the Bergen (A) and TCGA (B) cohorts, respectively. The entire
set of 473,864 CpGs was used for principal component analysis. The
heatmaps indicate the association of a sample annotation to each of the
principal components. The strength of association is specified by the
log10 p-value of the linear model with the respective principal
component as dependent variable and sample annotation as regressor.
DNAconc = DNA concentration. Technical variables of TCGA data are
termed as defined by the TCGA consortium. TCGA = The Cancer Genome
Atlas Consortium. Abbreviations as in Figure 1 of the main manuscript.
(C) Sample overlap when using different CpG sets for group discovery in
Bergen and TCGA data, respectively. For group discovery we used CpGs
Lauss et al. BMC Medical Genomics  (2015) 8:73 Page 9 of 11
with variant methylation between melanoma and melanocytes. CpGs
were required to be either methylated or de-methylated in at least 10
tumors for our final subtypes. The CpG set for 10 tumors contained 9,886
melanoma-methylated and 5,236 melanoma-demethylated CpGs. The
heatmap displays the overlap of the resulting three consensus clusters at
various tumor cutoffs. (D) Heatmap of TCGA sample co-occurrence
between unsupervised consensus clusters and methylation subtypes
obtained from (supervised) nearest centroid classification. Figure S2.
Promoter island consensus clusters. The group discovery CpG set was
reduced to CpGs located within 1500 bp upstream of transcription start
sites and within a CpG island. In total this analysis includes 947 CpGs, of
which 930 are hypermethylated, and 17 are hypomethylated in tumors as
compared to melanocytes. Two-group consensus solutions were
favorable to three-group solutions in Bergen and TCGA data, respectively.
Figure S3. Signature expression across methylation subtypes in TCGA
data. (A) ESTIMATE scores and tumor purity. P-value from Kruskal-Wallis
test. (B) Mean expression values of gene modules and GO-term ‘cell
cycle’. P-value from anova. TCGA tumor data. Figure S4. Aberrant
methylation in melanoma compared to colon, lung and breast cancer.
(A) Venn diagrams of aberrant methylation on the CpG and gene level.
(B) Aberrant methylation in ES-cell chromatin context. Chromatin
categories as in ENCODE project. (C) Aberrant methylation in melanocyte
chromatin context. Chromatin categories as in Epigenome Roadmap
project. Figure S5. Driver gene mutations and methylation subtypes in
the TCGA cohort. (A) Number of non-silent mutations per sample across
methylation subtypes. (B) Non-silent and hotspot mutations of reported
melanoma driver genes across subtypes. Figure S6. Expression of MAPK
and PI(3)K pathway genes across methylation subtypes. (A) Expression of
MAPK and PI(3)K pathway. fdr = false discovery rate for p-values from
anova using Benjamini-Hochberg adjustment. (B) Cross-table of gene
expression and methylation subtypes. (PDF 865 kb)
Additional file 2: Table S1. Centroids of methylation subgroups.
(XLS 1550 kb)
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